neffy® adrenaline nasal spray is now approved and available in Australia for anaphylaxis treatment in adults & children 15kg+. Needle-free option hailed by experts amid rising cases learn more about this breakthrough from CSL Seqirus
Written By: Nikita Chaudhari BPharm
Reviewed By: Pharmacally Editorial Team
CSL Seqirus, a division of Australia’s leading biotechnology company CSL, has announced the approval and immediate availability of neffy® adrenaline (epinephrine) nasal spray in Australia. This marks the first new adrenaline delivery method approved in the country in over 30 years, offering a needle-free option for emergency treatment of anaphylaxis in adults and children weighing 15kg or more and aged four years and over.
CSL Seqirus Executive Medical Director International and GP, Dr. Jonathan Anderson, expressed pride in the Australian innovation. “This is a proud day for CSL Seqirus. We’re collaborating with stakeholders to prepare clinicians, consumers, and schools, and we await the March 2026 review of our Pharmaceutical Benefits Scheme (PBS) application to broaden access.”
Anaphylaxis a potentially life-threatening reaction triggered by allergens like food, medications, or insect stings requires rapid intervention. Adrenaline quickly counters symptoms by reducing throat swelling, opening airways, and stabilizing heart function and blood pressure. Yet rates of anaphylaxis are surging: Australia boasts one of the highest hospital admission rates globally, with a 51% rise in emergency department visits and 35% increase in hospitalizations between 2015 and 2020.
Leading NSW allergist Professor Connie Katelaris AM hailed the approval as a gamechanger. “neffy provides patients and doctors with a nasal administration choice, addressing real challenges in anaphylaxis management,” she said. “It’s been available overseas for some time now Australians can access it too.”
Maria Said AM, Health Strategy and Advocacy Manager at Allergy & Anaphylaxis Australia, emphasized the daily burdens of the condition. “A non-injection option empowers those at risk and their doctors to select the best device. From restaurant meals to school camps, life demands constant vigilance but quick response is key when accidents occur.”
- Usage: Administer at the first signs of anaphylaxis; seek emergency care immediately afterward.
- Availability: Prescription-only, registered medicine not to be withheld if needed. Discuss options with a clinician.
- Side Effects: Common ones include headache, nasal discomfort, throat irritation, and feeling jittery. All medicines carry risks.
- PBS Status: CSL’s subsidy application is under review for March 2026.
Healthcare organizations are updating anaphylaxis resources and education materials to include neffy check their websites for details.
This launch offers hope for better preparedness amid rising anaphylaxis cases, potentially transforming emergency responses for millions at risk.
Reference
neffy, adrenaline nasal spray, now approved to treat anaphylaxis in Australia, 16 February 2026, News Releases | CSL
neffy, TGA Approved Consumer Information, pdf